Postoperative pathological complete response in a patient with PD‑L1‑negative stage IIIB lung squamous cell carcinoma following neoadjuvant tislelizumab treatment combined with chemotherapy: A case report and literature review

• DOI: 10.3892/ol.2023.13974
• Publication Date: 2023-07-24T12:16:10Z
• Authors: Guanghua Cui; Di Qu; Yun Bai; Xiaoke Sun; Yingjue Li; Yu Yang

The utilization of immune checkpoint inhibitors in oncological treatment has increased recent years. therapeutic strategy targeting the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway altered management advanced non-small cell lung carcinoma (NSCLC). Tislelizumab, a novel anti-PD-1 monoclonal antibody developed China, demonstrated efficacy treating NSCLC. However, its potential role as neoadjuvant therapy for locally NSCLC not been definitively established. Current guidelines do specify which patient populations may gain most benefit from immunotherapy coupled with chemotherapy, nor they indicate optimal timing, dose or duration adjuvant maintenance post-NSCLC surgery. Similarly, data concerning safety and practicability surgical resection following tislelizumab remain limited. present study describes case diagnosed stage IIIB NSCLC, was initially deemed unresectable. A preoperative biopsy tumor mass revealed squamous negative PD-L1 gene test. Notably, after two cycles exhibited marked shrinkage. This permitted to undergo thoracoscopic radical cancer resection, resulted pathological complete response. Postoperative pathology identified large infiltration lymphoplasmacytic cells foamy histiocytes. experienced grade 2 myelosuppression, condition that successfully addressed administration recombinant human granulocyte colony-stimulating factor. indicates feasibility integrated chemotherapy patients advanced, PD-L1-negative prior intervention. Moreover, suggests this combination alter microenvironment. generalization these findings necessitates further validation through randomized multicenter trials.